home / stock / bcab / bcab news

BCAB News and Press, BioAtla Inc. From 04/24/25

Stock Information
Company Name: BioAtla Inc.
Stock Symbol: BCAB
Market: NASDAQ
Website: bioatla.com
Menu
BCAB BCAB Quote BCAB Short BCAB News BCAB Articles BCAB Message Board
Get BCAB Alerts

News, Short Squeeze, Breakout and More Instantly...
BCAB - BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentation...
BCAB - BioAtla Announces Upcoming Poster Presentation at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting

SAN DIEGO, April 23, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB) , a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced a poster presentation at the up...

BCAB - BioAtla, Inc. (BCAB) Q4 2024 Earnings Call Transcript

2025-03-27 18:18:03 ET BioAtla, Inc. (BCAB) Q4 2024 Earnings Conference Call March 27, 2025 4:30 p.m. ET Company Participants Bruce Mackle - LifeSci Advisors, Investor Relations Jay Short - Chairman, Chief Executive Officer and Cofounder Richard Waldron - Chief F...

BCAB - BioAtla announces 30% workforce reduction

2025-03-27 17:12:20 ET More on BioAtla BioAtla reports Q4 results Seeking Alpha’s Quant Rating on BioAtla Historical earnings data for BioAtla Financial information for BioAtla Read the full article on Seeking Alpha For further details ...
BCAB - BioAtla Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Progress

CAB-EpCAM x CAB-CD3 (BA3182) Phase 1 dose-escalation study continues with data readout expected mid-2025; Dose expansion data readout anticipated 1H 2026 Mecbotamab vedotin (CAB-AXL-ADC) Q2W dosing regimen associated with exceptional overall survival (OS) with 66% and 58% of patients ...

BCAB - Expected US Company Earnings on Thursday, March 27th, 2025

HG Holdings Inc (STLY) is expected to report for quarter end 2024-12-31 Savara Inc. (SVRA) is expected to report $-0.11 for Q4 2024 Reborn Coffee Inc. (REBN) is expected to report for quarter end 2024-12-31 VSee Health Inc. (VSEE) is expected to report for Q4 2024 IceCure Medical ...

BCAB - BioAtla Announces Two Poster Presentations at Upcoming Medical Meetings

SAN DIEGO, March 20, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced two abstracts accepted for poster pr...
BCAB - BioAtla to Announce Fourth Quarter and Full-Year 2024 Financial Results and Provide Business Highlights on March 27, 2025

SAN DIEGO, March 19, 2025 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced that it plans to host a conference c...

Previous 10 Next 10